Sensydia, a Los Angeles, CA-based non-invasive cardiac assessment company, raised $8M in funding.
The round was led by Orlando Health Ventures, with participation from Colle Capital, Frontier Venture Capital, and others. Concurrent with this financing, Erick Hawkins, Chief Administrative Officer for Orlando Health, will join the Sensydia board of directors.
The company intends to use the funds to finalize the development of the CPS platform and submit to the United States Food and Drug Administration (FDA) in 2024 for prioritized review as part of the FDA Breakthrough Devices Program.
Led by Anthony Arnold, President and CEO, Sensydia intends to expand access to cardiac performance assessment outside the hospital’s catheterization lab with its non-invasive Cardiac Performance System (CPS). The platform delivers accurate, non-invasive assessment of cardiac performance (cardiac output, ejection fraction, and pulmonary pressures) almost anywhere in under 5 minutes. CPS utilizes proprietary waveform machine learning methods that have been trained against gold-standard measurements from in-hospital catheterization lab data.
In 2018, Sensydia received FDA 510(k) clearance for non-invasive measurement of ejection fraction by CPS, and in 2022, Sensydia CPS was granted Breakthrough Device Designation by the FDA.
FinSMEs
09/05/2023